The original disclosure in Japanese was released on August 6, 2019 at 15:00 (GMT+8)

Consolidated Financial Statements for the First Quarter Ended June 30, 2019
FY2020 (April 1, 2019 - March 31, 2020) [UNAUDITED]

August 6, 2019
Takara Bio Inc.
Tokyo Stock Exchange (1st section)4974
http://www.takara-bio.co.jp
Koichi Nakao, President
Shuichiro Matsuzaki, Executive Vice President
Tel. (077) 565-6970
August 9, 2019

Company name:
Stock exchange listings:
Code number:
URL:
Company representative:
Contact:

Scheduled date of quarterly statement filing:
Scheduled date of starting delivery of dividends:－
Supplementary documents of the financial results:
Yes
Financial results information meeting:No
Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles andpractices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.
1. Results for the three months ended June 30, 2019 (Apr. 1, 2019 – Jun. 30, 2019)(1) Consolidated operating results(Percentages indicate changes from the same period of the previous fiscal year.)Three months ended
Jun. 30, 2019

Net sales
Operating income
Ordinary income
Net income (loss) attributable to owners of theparent
Net income per share (in yen)
Fully diluted net income per share (in yen)
Note: Comprehensive income(Millions of yen)
8,650
2,251
2,200
1,591

(2) Consolidated financial position
Total assets
Net assets
Equity ratio (%)
Net assets per share (in yen)
(Reference) Equity

13.22
－
1,778

(%)

Three months ended
Jun. 30, 2018

(%)

(2.2)
45.8
41.1
54.2

(Millions of yen)
8,847
1,544
1,559
1,032

39.2
487.8
442.0
－

(－%)

8.57
－
(495)

(－%)

As of Jun. 30, 2019
(Millions of yen)

As of Mar. 31, 2018
(Millions of yen)

71,402
65,15491.1
540.3165,061

71,04064,09590.1
531.5764,0092. Dividends
Year ended
Mar. 31, 2019

Annual dividends per share in yen
Year ending
Year ending
Mar. 31, 2020
Mar. 31, 2020 (Forecast)First quarter end－－
Second quarter end
0.00
Third quarter end－
Year end
7.00
Annual7.00
Note: No revision of dividend payment forecast since the most recently announced payment forecast.

0.00
－

8.00
8.00

The original disclosure in Japanese was released on August 6, 2019 at 15:00 (GMT+8)
3. Forecast for the year ending March 31, 2020 (Apr. 1, 2019 – Mar. 31, 2020)(Percentages indicated changes from the same period of the previous fiscal year.)Six months ending Sep. 30, 2019
(Millions of yen)(%)

Year ending Mar. 31, 2020

(Millions of yen)

Net sales
17,129(1.4)
36,000Operating income
2,917
11.2
6,200
Ordinary income
3,001
12.4
6,450
Net income attributable to
1,950
13.3
4,250
owners of the parent
Net income per share (in yen)
16.20
35.29
Note: No revision of financial forecast since the most recently announced payment forecast.
※

(%)
0.4
13.5
13.9
16.2

Others(1) Changes in subsidiaries during the three months ended June 30, 2019
(Changes in specified subsidiaries resulting in change of scope) ： No
Newly included: － (Name)
Excluded: － (Name)(2) Application of special accounting methods to the consolidated quarterly financial statements ： No
(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement
1) Changes based on revisions of accounting standard： Yes
2) Changes other than ones based on revisions of accounting standard： No
3) Changes in accounting estimates： No4) Restatement： No
Note: For details, please see 2. Consolidated Quarterly Financial Statements and Important Notes (4) Notes toConsolidated Quarterly Financial Statements (Changes in Accounting Policies) on page 9 of the attached document.
(4) Number of outstanding shares (Common stock)1) Number of outstanding shares at year end (Treasury stocks are included)
120,415,600
As of June 30, 2019
120,415,600
As of March 31, 2018
2) Number of treasury stocks at year end－
As of June 30, 2019－
As of March 31, 2018
3) Average number of outstanding shares
120,415,600
As of June 30, 2019
120,415,600
As of June 30, 2018

※ These financial statements are not subject to auditing.
※ Comment regarding appropriate use of earnings forecasts and other special notes
Forward-looking statements contained in this document are determined by the Takara Bio Company based on information
currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due
to changes in conditions that occur in the future. For information regarding the above, please refer to 1. Qualitative Information
for the three months ended June 30, 2019 (4) Qualitative Information Regarding Consolidated Forecasts, on page 3 of theattached document.

The original disclosure in Japanese was released on August 6, 2019 at 15:00 (GMT+8)
Contents of the attached document
1. Qualitative Information for the three months ended June 30, 2019…………………………...........………………………...
2(1) Overview of Financial Results……………………………………………………….………….………….…………......
2(2) Overview of Financial Position………………………………………………...…………………………...……..............
2(3) Overview of Cash Flows…………………………………………………………….…………………………….……....
3(4) Qualitative Information Regarding Consolidated Forecasts………………………………………………………………
3
2. Consolidated Quarterly Financial Statements and Primary Notes…………………………………………………………….
4(1) Consolidated Quarterly Balance Sheets…………………………………………………………………………………...
4(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income…….
6(Consolidated Quarterly Statements of Income) …………………………………………………………………........... 6(For the three months ended June 30, 2019)(Consolidated Quarterly Statements of Comprehensive Income) ………………………………………………………
7(For the three months ended June 30, 2019)(3) Consolidated Quarterly Statements of Cash Flows………………………………………………………………………..
8(4) Notes to Consolidated Quarterly Financial Statements…………………………………………………………………… 9(Notes on Premise of Going Concern) …………………………………………………………………………………..
9(Notes in case of Changes in Marked Amount of Shareholders’ Equity)………………………………………………..
9(Changes in Accounting Policies)…………………………………………………………………………………..……
9(Segment Information) ………………………………………………………………………………………………….. 10
3. Supplementary Information ………………………………………………………………………………………………….. 11(1) Trends in Key Management Indicators…………………………………………………………………………………… 11(2) Comparative Consolidated Statement of Income ………………………………………………………………………… 12- 1 -The original disclosure in Japanese was released on August 6, 2019 at 15:00 (GMT+8)
1. Overview of Financial Results for the three months ended June 30, 2019(1) Overview of Financial Results
In the three months ended June 30, 2019, the Japanese economy continues to be unpredictable due to the protracted trade friction
issue in the U.S. and China, upsurge of geopolitical risks and others, in addition to weakening export and production and standstill
economy growth.
Under these circumstances, facing the last year of the three-year Takara Bio’s Medium-Term Management Plan FY2020 started
in FY2018, the Takara Bio Company (the Company) made the efforts toward the overall policy to enhance our presence as a global
enterprise and regenerative medical product company, and achieve prodigious growth.
As a result, overall net sales in the three months ended June 30, 2019 decreased 2.2% year on year to ¥8,650 million, due to adecrease in sales of scientific instruments and influence of business transfers related to functional food and mushroom in the
AgriBio Business Unit despite contributions from sales for research reagents and contracted services exceeding those of the same
period of the previous fiscal year. Cost of sales decreased 21.7% year on year to ¥2,734 million due to a decrease of cost percentage
from change of sales composition by item and others, and gross profit increased 10.5% year on year to ¥5,916 million. Selling,
general and administrative (SG&A) expenses decreased 3.8% year on year to ¥3,664 million due to the decrease in R&D expenses,
and the Company recorded operating income up 45.8% year on year to ¥2,251 million.
Accompanied with the increase in operating income, ordinary income increased 41.1% to ¥2,200 million, income before income
taxes and others increased 41.6% year on year to ¥2,191 million, and net income attributable to owners of the parent increased
54.2% year on year to ¥1,591 million.
The statuses of the Company business segments are as follows.
Bioindustry Business
Given the ever-widening activities of biotechnology R&D, the Company has positioned the the Bioindustry Business as its corebusiness, which mainly develops and provides products and services supporting such R&D activities.
In the three months ended June 30, 2019, sales of scientific instruments decreased year on year, but sales of research reagentsand contracted service increased year on year.
As a result of the above, sales to external customers for this business increased 3.5% year on year to ¥6,746 million, and grossprofit increased 18.8% year on year to ¥4,204 million due to a decrease of cost percentage from change of sales composition byitem and others. SG&A expenses increased 0.8% year on year to ¥2,873 million due to the increase in personnel expenses, but theCompany recorded operating income up 93.2% year on year to ¥1,331 million.
Gene Therapy Business
The business focuses on clinical development of gene therapies for diseases such as cancer. These therapies represent the
oncolytic virus therapy utilizing C-REV and the engineered T cell therapy utilizing the Company’s original technologies
such as the RetroNectin method for a high efficiency gene transduction; the RetroNectin expansion-culture system for ahigh efficient expansion for lymphocytes; as well as siTCR TM.
In the three months ended June 30, 2019, the licensing fees for domestic co-development and exclusive sales related to NY-ESO1・siTCRTM and CD19・CAR gene therapy products was generated, but the sales of the investigational products based on theagreement was decreased.
As a result, net sales to external customers for this business decreased 1.4% year on year to ¥1,903 million, and gross profit
decreased 1.9% year on year ¥1,711 million. However, SG&A expenses decreased 19.7% year on year to ¥242 million due todecrease in R&D expenses. Accordingly, operating income increased 1.8% year on year to ¥1,468 million.
(2) Overview of Financial Position
In the three months ended June 30, 2019, total assets were ¥71,402 million, an increase of ¥362 million compared with that at theend of the previous fiscal year. This primarily resulted from an increase of ¥2,756 million in cash and deposits despite decreases innotes and accounts receivable-trade of ¥2,316 million and intangible assets of ¥231 million.
Total liabilities were ¥6,248 million, a decrease of ¥696 million compared with that at the end of the previous fiscal year. This
primarily resulted from a decrease of ¥556 million in notes and accounts payable-trade.
Total net assets stood at ¥65,154 million, an increase of ¥1,058 million compared with that at the end of the previous fiscal year.
The main factors were an increase of ¥871 million in retained earnings.

- 2 -The original disclosure in Japanese was released on August 6, 2019 at 15:00 (GMT+8)(3) Overview of Cash FlowsNet cash provided by operating activities was ¥3,874 million, up by ¥919 million compared with the previous fiscal year. This wasprimarily due to an increase of ¥643 million in income before income taxes and others.
Net cash provided by investing activities was ¥11 million, a decrease of ¥2,543 million, a transition from expenditure to revenue
compared with the same period of the previous fiscal year. This was primarily due to increase of ¥201 million in proceeds fromtime deposits and increase of ¥99 million in proceeds from sales of property, plant and equipment and intangible assets, in addition
to the elimination of ¥1,836 million from payments for time deposits and decreases of ¥382 million in purchase of property, plantand equipment and intangible assets.
Net cash used in financing activities was ¥821 million, an increase of ¥313 million compared with the previous fiscal year. Thiswas primarily because of an increase of ¥294 million in cash dividends paid.
As a result of the above, cash and cash equivalents at the period ended June 30, 2019, including the effect of exchange ratechange on cash and cash equivalents, stood at ¥12,558 million, up by ¥3,094 million from the previous fiscal year-end.
(4) Qualitative Information Regarding Consolidated Forecasts
Consolidated results for the three months ended June 30, 2019, exceeded the plan against all such as earning item (operating income,ordinary income and net income attributable to owners of the parent), but the Company will not be revising the consolidated forecast
announced on May 14, 2019 at present.

- 3 -The original disclosure in Japanese was released on August 6, 2019 at 15:00 (GMT+8)
2. Consolidated Quarterly Financial Statements and Primary Notes(1) Consolidated Quarterly Balance Sheets(Millions of yen)
As of Mar. 31, 2019

AssetsCurrent assets
Cash and deposits
Notes and accounts receivable-trade
Securities
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Allowance for doubtful accounts
Total current assets
Noncurrent assets
Property, plant and equipment
Buildings and structures
Accumulated depreciation
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation
Machinery, equipment and vehicles, net
Tools, furniture and fixtures
Accumulated depreciation
Tools, furniture and fixtures, net
LandConstruction in progress
Others
Accumulated depreciation
Others, net
Total Property, plant and equipment
Intangible assets
Goodwill
Other
Total intangible assets
Investments and other assets
Investments and other assets
Total investments and other assets
Total noncurrent assets
Total assets- 4 -As of Jun. 30, 201917,033
8,604
2,000
4,523
706
1,506
941
(41)
35,275

19,790
6,288
2,000
4,536
997
1,658
820
(41)
36,05011,775(5,435)6,340
5,510(3,745)
1,764
6,890(4,588)
2,302
6,213
4,784
15
(15)
－
21,404

11,588(5,266)
6,322
4,879(3,156)1,723
6,938(4,756)
2,181
6,113
4,812
698
(38)
659
21,812

7,598
5,029
12,628

7,479
4,917
12,396

1,732
1,732
35,76571,0401,143
1,14335,352
71,402

The original disclosure in Japanese was released on August 6, 2019 at 15:00 (GMT+8)(Millions of yen)
As of Jun. 30, 2019

As of Mar. 31, 2019
Liabilities
Current liabilities
Notes and accounts payable-trade
Accrued income taxes
Provision
Other
Total current liabilities
Noncurrent liabilities
Net defined benefit liability
Other
Total noncurrent liabilities
Total liabilities
Net assets
Shareholders’ equity
Share capital
Capital surplus
Retained earnings
Total shareholders' equity
Accumulated other comprehensive income
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Total accumulated other comprehensive income
Non-controlling interests
Total net assets
Total liabilities and net assets

- 5 -

1,536
391
593
3,495
6,017

980
489
825
2,911
5,207

667
260
927
6,945

685
355
1,041
6,248

14,96532,893
15,401
63,26014,96532,893
16,27264,131

964
(215)
749
85
64,09571,040

1,139
(208)
930
92
65,154
71,402

The original disclosure in Japanese was released on August 6, 2019 at 15:00 (GMT+8)(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income(Consolidated Quarterly Statements of Income)(For the three months ended June 30, 2019)(Millions of yen)Three months ended
Jun. 30, 2019

Three months ended
Jun. 30, 2018
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Employees' salaries and bonuses
Retirement benefit expenses
R&D expenses
Provision for allowances
Other
Total selling, general and administrative expenses
Operating income
Non-operating income
Interest income
Rent of Real estate
Other
Total non-operating income
Non-operating expenses
Foreign exchange losses
Real estate leasing expense
Other
Total non-operating expenses
Ordinary income
Extraordinary income
Gain on sales of noncurrent assets
Total extraordinary income
Extraordinary losses
Loss on sales and retirement of non-current assets
Loss on sale of investment securities
Total extraordinary losses
Income before income taxes and others
Income taxes-current
Income taxes-deferred
Total income taxes
Net income
Net income attributable to noncontrolling interest
Net income attributable to owners of the parent

- 6 -

8,847
3,491
5,355

8,650
2,734
5,916

986
44
1,014
132
1,632
3,811
1,544

1,000
47
939
140
1,537
3,664
2,251

18
23
8
49

22
24
14
62

23
5
5
34
1,559

96
6
9
113
2,200

－
－

0
0

10
－
10
1,548
702
(188)
514
1,034
2
1,032

6
2
9
2,191
545
49
595
1,596
4
1,591

The original disclosure in Japanese was released on August 6, 2019 at 15:00 (GMT+8)(Consolidated Quarterly Statements of Comprehensive Income)(For the three months ended June 30, 2019)(Millions of yen)Three months ended
Jun. 30, 2019

Three months ended
Jun. 30, 2018
Net income
Other comprehensive income
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to:
Owners of the parent
Non-controlling interest

- 7 -

1,034

1,596

(1,533)
3(1,530)
(495)

176
6
182
1,778

(490)
(5)

1,772
6

The original disclosure in Japanese was released on August 6, 2019 at 15:00 (GMT+8)(3) Consolidated Quarterly Statements of Cash Flows(Millions of Yen)

Three months ended
Jun. 30, 2018
Net cash provided by (used in) operating activities
Income before income taxes and others
Depreciation and amortization
Depreciation and amortization on other
Amortization of goodwill
Increase (decrease) in allowance for doubtful accounts
Increase (decrease) in other provision
Increase (decrease) in net defined benefit liability
Interest income
Loss (gain) on sales and retirement of non-current assets
Decrease (increase) in notes and accounts receivabletrade
Decrease (increase) in inventories
Increase (decrease) in notes and accounts payable-trade
Other
SubtotalInterest and dividend income received
Income taxes paid
Net cash provided by (used in) operating activities
Net cash provided by (used in) investing activities
Payments for time deposits
Proceeds from time deposits
Purchase of property, plant and equipment andintangible assets
Proceeds from sales of property, plant and equipment
and intangible assets
Purchase of other depreciable assets
Other
Net cash provided by (used in) investing activities
Net cash provided by (used in) financing activities
Cash dividends paid
Repayments of lease obligations
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period- 8 -Three months ended
Jun. 30, 2019
1,548
669
48
123
2
225
11
(18)
10

2,191
677
23
125
(0)
231
18
(22)
6

1,903

2,328

(818)
(184)
(167)
3,353
8
(407)
2,954

(419)
(565)
(377)
4,217
10
(353)
3,874

(2,000)
333

(163)
535

(829)

(447)

0

100

(35)
(0)
(2,531)

(11)
(1)
11

(508)
－
(508)
(364)
(450)
10,051
9,601

(803)
(18)
(821)
30
3,094
9,464
12,558

The original disclosure in Japanese was released on August 6, 2019 at 15:00 (GMT+8)(4) Notes to Consolidated Quarterly Financial Statements(Notes on Premise of Going Concern)
No items to report.
(Notes in case of Changes in Marked Amount of Shareholders’ Equity)
No items to report.
(Change in Accounting Policies)(Adoption of ASU2014-09 “Revenue from Contracts with Customers”)
The overseas subsidiaries which adopt U.S. GAAP adopted ASU2014-09 “Revenue from Contracts with Customers” (ASU201409) from the beginning of the year ending March 31, 2020. The Company adopts a method to recognize the cumulative effect of
ASU2014-09 adoption, which is recognized as a transitional measure, on the initial date of adoption.
Due to the adoption of ASU-2019-09, the revenue is recognized at the time the promised goods or services are transferred tocustomers, in an amount that reflects the consideration expected to be received in the exchange for those goods or services.
The impact on consolidated quarterly financial statement for the three months ended June 30, 2019 is immaterial.
(Adoption of IFRS16 “Leases”)
The overseas subsidiaries which adopt the International Financial reporting Standards (“IFRS”) adopted IFRS16 “Leases”(IFRS16) from the beginning of the year ending March 31, 2020. The Company adopts a method to recognize the cumulative
effect of IFRS16 “Leases” adoption, which is recognized as a transitional measure, on the initial date of adoption.
Due to the adoption of IFRS16, the Company principally recognizes assets and liabilities for all leases as a lessee.
Also, the land-use rights stated formerly in “Investments and other assets” has been classified as right-of -use assets from thethree months ended June 30, 2019.
Accordingly, increases by ¥644 million in “Other, net” for Property, plant and equipment, by ¥69 million in “Other” for current
liabilities, and by ¥79 million in “Other” for Noncurrent liabilities, and decrease by ¥469 million in “Investments and otherassets” have been allocated.
The impact on profit and loss for the three months ended June 30, 2019 is immaterial.

9The original disclosure in Japanese was released on August 6, 2019 at 15:00 (GMT+8)(Segment Information)
I. Equivalent period of previous fiscal year (From Apr. 1, 2018, to Jun. 30, 2018)
1. Net sales and income (loss) by reportable segment(Millions of yen)Amountrecognized inconsolidated
Adjustment(Note: 1) quarterly financial
statements(Note: 2)

Reportable segment
Total

Bioindustry

Gene
Therapy

AgriBio

6,516
－

1,931
－

399
－

8,847
－

－
－

8,847
－

6,516

1,931

399

8,847

－

8,847

Net sales
External customers
Corporate
Total

Segment income (loss)
689
(45)
2,086
(541)
1,544
1,442
Notes: 1. The adjustment for segment income (loss) was a loss of ¥541 million comprising of the Company not allocated toreportable segments. Expenses of the Company primarily consist of general and administrative expenses and R&D
expenses not attributed to reportable segments.
2. Segment income (loss) has been adjusted to the operating income of consolidated quarterly financial statements.
II. Three months ended June 30, 2019 (From Apr. 1, 2019, to Jun. 30, 2019)
1. Net sales and income (loss) by reportable segment(Millions of yen)
Reportable segment
Total

Amount recognizedin consolidated
Adjustment
quarterly financial(Note: 1)statements(Note: 2)

Bioindustry

Gene
Therapy

6,746
－

1,903
－

8,650
－

－
－

8,650
－

6,746

1,903

8,650

－

8,650

Net sales
External customers
Corporate
Total

Segment income
1,331
1,468
2,800
(548)
2,251
Notes: 1. The adjustment for segment income was a loss of ¥548 million comprising of the Company not allocated to reportablesegments. Expenses of the Company primarily consist of general and administrative expenses and R&D expenses
not attributed to reportable segments.
2. Segment income has been adjusted to the operating income of consolidated quarterly financial statements.
2. Information about impairment loss for non-current assets and goodwill by reportable segment
No items to report.
3. Matters related to changes and others by reportable segment
The reportable segment “AgriBio Business” has been eliminated from the three months ended June 30, 2019 due to thebusiness transfers related to functional food and mushroom in AgriBio Business Unit for the previous fiscal year.

10The original disclosure in Japanese was released on August 6, 2019 at 15:00 (GMT+8)
3. Supplementary Information(1) Trends in Key Management Indicators1). Cash Flow
Three months ended
Jun. 30, 2018
Term
(Apr. 1, 2018 - Jun. 30, 2018)
Net cash provided by (used in)(Millions of yen)Three months ended
Year ended Mar. 31, 2019
Jun. 30, 2019
(Apr. 1, 2018 - Mar. 31, 2019)(Apr. 1, 2019 - Jun. 30, 2019)

2,954

3,874

5,783

Net cash provided by (used in)investing activities(2,531)

11(5,576)

Net cash provided by (used in)financing activities

(508)

(821)

(541)

operating activities

2). Net Sales by Region

Three months ended
Three months ended
Jun. 30, 2018
Jun. 30, 2019
(Apr. 1, 2018 - Jun. 30, 2018) (Apr. 1, 2019 - Jun. 30, 2019)(Millions of yen)
Year ended Mar. 31, 2019
(Apr. 1, 2018 - Mar. 31, 2019)

Japan

4,248

3,937

16,101

U.S.

1,995

1,955

7,945

China

1,307

1,427

6,227

410

474

1,994

811

784

3,328

Asia excluding Japan and
China
Europe
Other
Total

73

72

244

8,847

8,650

35,8413). R&D Expenses by Reportable Segment
Three months ended
Jun. 30, 2018
(Apr. 1, 2018 - Jun. 30, 2018)(Millions of yen)Three months ended
Year ended Mar. 31, 2019
Jun. 30, 2019
(Apr. 1, 2018 - Mar. 31, 2019)(Apr. 1, 2019 - Jun. 30, 2019)

Bioindustry

670

676

2,723

Gene therapy

298

223

1,391

Corporate

45

39

222

1,014

939

4,337

Total

- 11 -

The original disclosure in Japanese was released on August 6, 2019 at 15:00 (GMT+8)(2) Comparative Consolidated Statement of Income
Three months ended
Jun. 30, 2018
Actual（Net Sales）(Rounded down to one million yen)Three months ended
Year on year
Year on year
Jun. 30, 2019
ChangeRatio
ActualResearch reagents
Scientific instruments
Contracted services
Other
Bioindustry Total
Gene therapy
Other (Former AgriBio)

5,246
517
630
122
6,516
1,931
399

5,584
274
781
107
6,746
1,903
－

337
(243)
151
(15)
230
(27)
(399)

106.4%
53.0%
124.1%
87.6%
103.5%
98.6%－

Total net sales

8,847

8,650

(196)

97.8%

(Operating Income and Loss)
Net sales

8,847

8,650

(196)

97.8%

Cost of sales

3,491

2,734

(757)

78.3%

Gross profits

5,355

5,916

560

110.5%

SG&A expenses

3,811

3,664

(146)

96.2%

Transportation expenses
Advertising expenses
Promotion expenses
R&D expenses
Administrative expenses, other
Enterprise taxes (external standards taxation)

158
16
164
1,014
2,365
92

89
17
136
939
2,399
81

(68)
1
(27)
(75)
33
(10)

56.8%
110.8%
83.2%
92.6%
101.4%
88.5%

Operating income

1,544

2,251

707

145.8%

4962

12

125.3%(Non-operating Income and Expenses)
Non-operating income
Non-operating expenses
Ordinary income(Extraordinary Income & Losses)
Extraordinary income
Extraordinary losses
Income before income taxes and others
Income taxes
Net Income
Net income (loss) attributable to non-controllinginterests
Net income attributable to owners of the parent

34

113

78

324.6%

1,559

2,200

641

141.1%

－

0

0

－

10

9

(1)

85.7%

1,548

2,191

643

141.6%

514

595

81

115.9%

1,034

1,596

561

154.3%

2

4

2

222.4%

1,032

1,591

559

154.2%

669

677

7

101.2%

123

125

2

101.8%

Three months ended
Jun. 30, 2018
ActualThree months ended
Jun. 30, 2019
ActualYear on year
ChangeYear on year
Ratio

689
1,442
(45)
(541)

1,331
1,468
－
(548)

642
26
45
(7)

193.2%
101.8%
－
－

1,544

2,251

707

145.8%

Depreciation and amortization (Property, plant andequipment and intangible assets)
Amortization of goodwill
Profit and loss by business segment (Operating income)Bioindustry
Gene therapy
Other (Former AgriBio)
Corporate
Total- 12 -